Segall Bryant & Hamill LLC Has $12.96 Million Stock Holdings in AngioDynamics, Inc. (NASDAQ:ANGO)

Segall Bryant & Hamill LLC boosted its position in shares of AngioDynamics, Inc. (NASDAQ:ANGO) by 55.3% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 1,415,156 shares of the medical instruments supplier’s stock after purchasing an additional 503,713 shares during the quarter. Segall Bryant & Hamill LLC owned about 3.50% of AngioDynamics worth $12,963,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently added to or reduced their stakes in the business. American Century Companies Inc. raised its stake in shares of AngioDynamics by 22.1% during the fourth quarter. American Century Companies Inc. now owns 67,942 shares of the medical instruments supplier’s stock worth $622,000 after buying an additional 12,306 shares during the last quarter. Intech Investment Management LLC acquired a new stake in AngioDynamics during the 4th quarter worth $152,000. Royce & Associates LP raised its position in shares of AngioDynamics by 13.5% during the 4th quarter. Royce & Associates LP now owns 1,119,385 shares of the medical instruments supplier’s stock valued at $10,254,000 after acquiring an additional 133,312 shares during the last quarter. First Eagle Investment Management LLC lifted its stake in shares of AngioDynamics by 4.1% in the 4th quarter. First Eagle Investment Management LLC now owns 410,335 shares of the medical instruments supplier’s stock valued at $3,759,000 after purchasing an additional 16,221 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. boosted its position in shares of AngioDynamics by 69.0% in the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 389,053 shares of the medical instruments supplier’s stock worth $3,564,000 after purchasing an additional 158,897 shares during the last quarter. 89.43% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Separately, HC Wainwright increased their target price on AngioDynamics from $14.00 to $15.00 and gave the company a “buy” rating in a research note on Friday, January 10th.

AngioDynamics Stock Up 1.0 %

Shares of NASDAQ ANGO opened at $10.18 on Wednesday. AngioDynamics, Inc. has a twelve month low of $5.30 and a twelve month high of $13.50. The stock has a market cap of $411.94 million, a price-to-earnings ratio of -1.81 and a beta of 0.56. The company’s fifty day moving average is $10.57 and its 200-day moving average is $8.76.

AngioDynamics (NASDAQ:ANGO) last posted its earnings results on Wednesday, January 8th. The medical instruments supplier reported ($0.04) earnings per share for the quarter, topping the consensus estimate of ($0.11) by $0.07. The firm had revenue of $72.90 million for the quarter, compared to analyst estimates of $70.93 million. AngioDynamics had a negative return on equity of 7.26% and a negative net margin of 79.38%. The company’s revenue for the quarter was down .1% on a year-over-year basis. During the same period in the previous year, the company posted ($0.05) earnings per share. On average, research analysts anticipate that AngioDynamics, Inc. will post -0.37 EPS for the current fiscal year.

Insider Buying and Selling

In other news, SVP Warren Nighan, Jr. sold 4,060 shares of the company’s stock in a transaction dated Thursday, January 16th. The stock was sold at an average price of $12.31, for a total transaction of $49,978.60. Following the completion of the transaction, the senior vice president now directly owns 41,817 shares of the company’s stock, valued at $514,767.27. This represents a 8.85 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 5.40% of the company’s stock.

AngioDynamics Company Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.